OMITTED

What the news leaves out.

← Omitted front page

Trump Extends Most-Favored-Nation Drug Pricing to Medicaid

7 sources · updated 2026-09-20
Left 50% Center 0% Right 50%
3 left · 0 center · 3 right

What happened

President Donald Trump announced Friday in the Oval Office that Medicaid programs in all 50 states, Washington, D.C., and Puerto Rico will receive “most favored nation” (MFN) pricing on some brand-name drugs under a model the administration calls GENEROUS, so Medicaid’s net price would not exceed prices paid in certain other high-income countries. The step extends deals Trump has reached with 26 pharmaceutical companies after an executive order last year aimed at aligning U.S. prices with those in other affluent nations; the Centers for Medicare and Medicaid Services said 40 states and Puerto Rico have already signed agreements, with the rest having applied. Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., CMS Administrator Mehmet Oz, and several governors. The White House Council of Economic Advisers estimated the Medicaid extension would save about $64 billion over 10 years, and the administration has estimated the broader MFN initiative could save $529 billion over a decade. Medicaid enrollees already pay only a nominal copayment to fill prescriptions, so any savings would accrue mainly to state and federal program budgets.
Sourcing check · Fully on the record · 6 articles

6 of 6 articles cite a named source for the story. It was on the record from the first report.

What these terms mean and how they're counted
On the record · names a source 6 of 6
On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: President Trump, Robert F. Kennedy Jr., President Donald Trump, White House Council of Economic Advisers, Dr. Mehmet Oz and Donald Trump
Primary evidence · cites a document or data 1 of 6
Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: official announcement, economic estimate
Credits another outlet 0 of 6
The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
Unnamed sources 0 of 6
The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
How it developed
When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Sep 18, 18:05 UTC by The Hill, naming its source. First document 5 hours later, from New York Post (official announcement).
Not counted 0
Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out

Unpacked

Whether anyone can inspect the Medicaid savings is the split that matters. Left-leaning coverage warns that the figures cannot be audited; right-leaning coverage prints them as results. Independent experts cannot verify the projections because the drug-company deals remain unpublished, ABC News reports, and that absence blocks Congress from knowing what it would be asked to lock in. A White House estimate of $64 billion over ten years appears in the New York Post with no note that the contracts are secret. Right-leaning coverage describes force; left-leaning coverage describes a bargain. Manufacturers were "strong-armed" into matching foreign prices, the New York Post writes, while ABC News says the president has cut deals with them. What drugs are in the model, and what does Medicaid already pay for them after existing rebates?
Bottom line

All 50 states joining is the one fact both sides share. The New York Post's $64 billion Medicaid savings and ABC News' warning that the drug deals were never published do not appear in the same story.

The receipts — 6 facts one side's coverage lacks
  • The content of the pharmaceutical deals is not public, making it hard to independently verify projected savings contextin ABC News · absent from right-leaning coverage
  • $64 billion in estimated Medicaid savings over 10 years numberin The New York Post, Breitbart · absent from left-leaning coverage
  • Medicaid patients already pay a nominal copayment of a few dollars contextin ABC News · absent from right-leaning coverage
  • Deals struck with 26 pharmaceutical companies numberin The New York Post, Breitbart · absent from left-leaning coverage
  • Forty states and Puerto Rico have already signed agreements numberin The Hill · absent from right-leaning coverage
  • GENEROUS model rebates will ensure the final Medicaid price does not exceed the MFN price on expensive brand-name drugs official statementin Breitbart · absent from left-leaning coverage
The Left View
Left-leaning outlets framed the announcement as a midterms-season affordability pitch whose dollar claims cannot yet be checked. ABC News reported that experts say the savings are unclear because the deals’ contents have not been made public, “making it hard to independently verify the projected savings.” Kathy Hempstead of the Robert Wood Johnson Foundation said it is “kind of unreasonable” to ask Congress to codify the MFN arrangements when “no one knows what is in these deals,” and she flagged concern that prices could revert after the administration leaves. Coverage also stressed that lower acquisition costs would mainly ease state budgets rather than patients’ out-of-pocket costs, and JD Hayworth of the Pharmaceutical Reform Alliance called the move “meaningful progress, but that progress remains incomplete” for Americans not enrolled in government coverage.
The Right View
Right-leaning outlets presented universal state participation as a rebuke of critics and a large fiscal win. The New York Post quoted Trump saying jurisdictions “all succumbed to the dollar,” that “many left-wing critics predicted that the states would not participate” and “some of the blue states tried not to, but they couldn’t help it when you’re getting your drugs for 70, 80, 90% less,” and that “this one thing alone should win us the midterms.” Coverage highlighted the CEA’s Medicaid estimate and Oz’s claim that “we are rescuing state budgets with this program” because drug spending is “crowding out schools and roads.” Kennedy said the initiative matched what “my party was promising and prioritizing for decades” and was a “giant benefit for the poorest members of our society.”
Our Take (balanced)
The right’s strongest argument is that every state opted in—including Democratic ones that, in Trump’s telling, “tried not to”—which, together with the CEA’s 10-year figure and claimed 70–90% discounts, is offered as proof the terms deliver real budget relief. The left’s strongest argument is that those figures cannot be independently verified while deal terms remain unpublished; Hempstead’s point that “no one knows what is in these deals” undercuts both the savings claims and any push to have Congress codify them, and leaves open whether cuts survive this administration. The central unresolved tension is whether nationwide buy-in and White House estimates establish genuine, lasting Medicaid savings, or whether secrecy about the contracts leaves the size and durability of those savings unproven.

7 sources

More stories

The week's bottom lines, in your inbox

One email a week: the five stories that mattered and what they actually mean. Free.